Hormonal
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) including liraglutide, exenatide, semaglutide, and dulaglutide produce statistically significant weight loss in obese individuals, with intervention groups losing 5.1 to 6.16 kg compared to 1.6 to 3.97 kg in control groups.
If you are obese, GLP-1 receptor agonists like liraglutide or semaglutide are proven to help you lose weight significantly more than lifestyle changes alone. These medications work by mimicking a hormone that makes you feel full and slows down digestion. While they are injections, they have been shown to be safe and effective for adults aged 18-65, helping to reduce body fat and improve metabolic health.
individuals lost weight of about minimum of 5.1 kg and maximum of 6.16 kg in the intervention group or those who were observed to use any type of GLP-1Ras as opposed to 1.6 - 3.97 kg lost among those individuals who did not use any type of GLP-1Ras. These results with their respective effect sizes were statistically significant with a P-value of < 0.05.
Why this rating
Based on a systematic review of 20 studies including RCTs, though the review itself is qualitative rather than a meta-analysis.
Source
Efficacy of Glucagon-Like Peptide-1 Receptor Agonists in the Weight Loss Among Obese Individuals: A Systematic Review
Raed Aldahash · Journal of Endocrinology and Metabolism · 2021
DOI 10.14740/jem745
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →